Table 6 Post-hoc analysis (least significant difference) comparing ratio of serum IGF-1 and IGFBP-3 for each of the six CVMI stages

1

2

.001

0.8(NS)

3

−.018^*

0.01(NS)

4

−.001

0.8(NS)

5

−.012

0.09(NS)

6

.003

0.6(NS)

2

1

−.001

0.8(NS)

3

−.020^*

0.009(**)

4

−.003

0.6(NS)

5

−.014

0.05(NS)

6

.001

0.8(NS)

3

1

.018^*

0.016(*)

2

.020^*

0.009(**)

4

.016^*

0.029(*)

5

.005

0.4(NS)

6

.022^*

0.005(**)

4

1

.001

0.8(NS)

2

.003

0.6(NS)

3

−.016^*

0.029(*)

5

−.011

0.1(NS)

6

.005

0.4(NS)

5

1

.012

0.09(NS)

2

.014

0.05(NS)

3

−.005

0.4(NS)

4

.011

0.1(NS)

6

.016^*

0.035(*)

6

1

−.003

0.6(NS)

2

−.001

0.8(NS)

3

−.022^*

0.005(**)

4

−.005

0.4(NS)

5

−.016^*

0.035(*)